Sofosbuvir API Market

Sofosbuvir API Market Size, Share & Industry Analysis, By Purity (Above 98%, and Above 99%), By Application (Tablets, and Others) By End-User (Hospitals, Clinics, and Pharmacies), and Forecast Period 2025-2035

Sofosbuvir API market is experiencing a CAGR of 4.7% during the forecast period, driven by the increasing burden of Hepatitis C Virus (HCV) infections globally and the rising demand for effective antiviral drugs. The growing adoption of direct-acting antivirals (DAAs), with Sofosbuvir as a leading compound, continues to fuel demand across both developed and developing regions.

Tablets remain the dominant application segment, primarily due to their effectiveness in delivering fixed-dose combinations for HCV treatment. Among purity types, above 99% purity Sofosbuvir APIs are in high demand for their superior efficacy and quality assurance in pharmaceutical formulations. In terms of end-users, hospitals and pharmacies account for the majority of demand, owing to increasing prescription rates and institutional procurement of branded and generic Sofosbuvir-based drugs.

Regionally, Asia-Pacific is projected to witness the fastest growth owing to a high prevalence of Hepatitis C, expanding healthcare access, and the increasing availability of generic Sofosbuvir products in countries like India and China. India, in particular, plays a pivotal role due to its position as a global hub for generic pharmaceutical manufacturing and its proactive licensing strategies that support local and regional distribution.

Key players driving competition in the global Sofosbuvir API market include Gilead Sciences, the original patent holder, along with leading generic producers such as Hetero Drugs, Natco Pharma, Mylan, Cipla, Dr. Reddy’s Laboratories, Aurobindo Pharma, and Sun Pharmaceutical Industries. These companies are engaged in bulk production and export of Sofosbuvir API, ensuring widespread accessibility, especially in low- and middle-income countries.

Seeking Comprehensive Intelligence on Different markets? Get in Touch with our Experts

Report Scope & Segmentation

  1. Introduction
  • Overview of Sofosbuvir API
  • Key End-Users & Industry Use Cases
  • Market Scope & Study Objectives
  1. Market Overview
  • Global Market Size & Growth Trends (Historical & Forecast)
  • Demand-Supply Dynamics
  1. Segmental Outlook
  • By Purity
    • Above 98%
    • Above 99%
  • By Application
    • Tablets
    • Others
  • Key End-Use Industries
  • Hospitals
  • Clinics
  • Pharmacies
  1. Price Analysis
  • Current Price Trends (Per kg & Per Ton)
  • Price Fluctuation Factors (Raw Material Costs, Production, Trade Tariffs)
  • Regional Price Comparison (North America, Europe, Asia-Pacific, and Other)
  1. Trade Analysis
  • Major Exporting & Importing Countries
  • Trade Volume & Value Statistics
  • Impact of Trade Regulations & Policies
  1. Regional Analysis
  • North America (US and Canada)
  • Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, Taiwan, India, and Rest of Asia-Pacific)
  • Rest of the World (Latin America, and Middle East, and Africa)
  1. Competitive Landscape
  • Top Global Manufacturers & Production Capacity
  • Company Profiles & Key Developments
    • Gilead Sciences
    • Hetero Drugs
    • Natco Pharma
    • Mylan
    • Cipla
    • Teva Pharmaceuticals
    • Dr. Reddy’s Laboratories
    • Aurobindo Pharma
    • Sun Pharmaceutical Industries
    • Alembic Pharmaceuticals
    • Lupin
    • Zydus Cadila
    • Divis Laboratories
    • Torrent Pharmaceuticals
    • Jubilant Life Sciences
    • Aspire Lifesciences Pvt Ltd
    • Century Pharmaceuticals
    • Beijing Huikang Boyuan Chemical Tech Co., Ltd
    • Fuxin Long Rui Pharmaceutical
    • Jiangsu Yutian Pharmaceutical
    • Haoyuan Chemexpress Co. Ltd
    • CHEMO
    • Hanways Chempharm Co., Limited
    • Guangzhou Tosun Pharmaceutical
    • CAD Middle East Pharmaceutical Industries LLC
    • Srini Pharmaceuticals
  • Mergers, Acquisitions & Investments
  1. Regulatory & Compliance Factors
  • FDA, REACH, and Other Regulatory Frameworks
  • Environmental & Safety Considerations
  • Emerging Policies Impacting Market Growth
  1. Conclusion & Strategic Recommendations
  • Key Takeaways for Stakeholders
  • Market Entry Strategies
What is Sofosbuvir?
Sofosbuvir is a direct-acting antiviral (DAA) used in the treatment of Hepatitis C Virus (HCV) infections. It works by inhibiting the HCV NS5B RNA-dependent RNA polymerase, a key enzyme for viral replication.
What is the market size for Sofosbuvir?
The Sofosbuvir API market is growing at a CAGR of 4.7% during the forecast period 2025-2035. Demand is driven by the rising global burden of HCV and widespread adoption of Sofosbuvir-based therapies.
What are the drivers for the Sofosbuvir Market?
Key drivers include increasing HCV infection rates, rising use of DAAs, and expansion of generic drug availability. Fixed-dose tablet combinations dominate due to their convenience and clinical success.
Who are the key players operating in the Sofosbuvir Market?
Major players include Gilead Sciences, Hetero Drugs, Natco Pharma, Mylan, Cipla, Dr. Reddy’s Laboratories, Aurobindo Pharma, and Sun Pharmaceutical Industries.
Which region would exhibit the fastest growth in the Sofosbuvir Market?
The Asia-Pacific region is expected to witness the fastest growth due to a high prevalence of HCV and improved access to generic treatments. India leads as a global manufacturing hub, supporting regional distribution.
$1800/- Single User License
$3600/- Multi User License

How can we help you?

Reach out to discuss how our team can help your business achieve real results.